fluocinolone acetonide / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 15 Diseases   9 Trials   9 Trials   230 News 


«123»
  • ||||||||||  ciprofloxacin oral / Generic mfg., fluocinolone acetonide / Generic mfg.
    Clinical, PK/PD data, Journal:  Pharmacokinetics of ciprofloxacin and fluocinolone acetonide otic solution in pediatric patients. (Pubmed Central) -  Sep 21, 2022   
    The FAc intravitreal implant is effective for 24 months, and sustained for 36 months, in a UAE population previously treated with a DEX implant, with tolerability profile in-line with previous reports. These results demonstrated negligible systemic exposure to ciprofloxacin and fluocinolone acetonide following topical otic administration in pediatric patients with AOMT.
  • ||||||||||  Journal:  Perspectives of topical formulations for melasma. (Pubmed Central) -  Sep 12, 2022   
    In conclusion, we have compiled specific topical therapies for treating melasma and discussed those that are the most used currently. We consider it important that prescribers and researchers evaluate the best cost-benefit ratio of topical therapeutic options and develop new formulations, enabling efficacy in the treatment with safety and comfort during application, through the reduction of adverse effects.
  • ||||||||||  ciprofloxacin oral / Generic mfg., fluocinolone acetonide / Generic mfg.
    Journal:  Two Validated Chromatographic Methods for Determination of Ciprofloxacin HCl, One of its Specified Impurities and Fluocinolone Acetonide in Newly Approved Otic Solution. (Pubmed Central) -  Sep 10, 2022   
    The second method was based on high-performance liquid chromatography using a Zorbax ODS column (5 μm, 150 × 4.6 mm i.d.) where adequate separation was achieved through a mobile phase composed of phosphate buffer pH 3.6-acetonitrile (45:55, v/v) at flow rate 1.0 mL min-1 with ultraviolet detection at 254 nm. Linear regressions were obtained in the range of 1.0-40.0 μg mL-1 for CIP, 0.6-20.0 μg mL-1 for FLU and 1.0-40.0 μg mL-1 for CIP-imp A. The suggested methods were validated in compliance with the International Conference on Harmonization guidelines and were successfully applied for determination of CIP and FLU in bulk powder and newly marketed otic solution.
  • ||||||||||  fluocinolone acetonide / Generic mfg.
    Journal:  Intravitreal fluocinolone acetonide implant for chronic postoperative cystoid macular edema - two years results. (Pubmed Central) -  Sep 7, 2022   
    Linear regressions were obtained in the range of 1.0-40.0 μg mL-1 for CIP, 0.6-20.0 μg mL-1 for FLU and 1.0-40.0 μg mL-1 for CIP-imp A. The suggested methods were validated in compliance with the International Conference on Harmonization guidelines and were successfully applied for determination of CIP and FLU in bulk powder and newly marketed otic solution. Visual and anatomic improvements were achieved by a single fluocinolone acetonide implant with few side effects up to 24 months in CME eyes with a long and heavy prior treatment history.
  • ||||||||||  fluocinolone acetonide / Generic mfg., dexamethasone injection / Generic mfg.
    Retrospective data, Journal:  Foveal eversion patterns in diabetic macular edema. (Pubmed Central) -  Aug 7, 2022   
    Foveal eversion patterns were correlated with progressively worse DME outcome. Foveal eversion may be associated to the loss of foveal homeostasis, with consequent poor response to intravitreal treatments and worse DME outcome.
  • ||||||||||  fluocinolone acetonide / Generic mfg.
    Journal:  TREATMENT OF BILATERAL DIFFUSE UVEAL MELANOCYTIC PROLIFERATION WITH INTRAVITREAL STEROID IMPLANTS. (Pubmed Central) -  Jun 30, 2022   
    Additional studies will be needed to determine which patients are the optimal candidates for this therapy. Intravitreal steroid implants resulted in visual acuity improvement and central retinal thickness reduction for up to 20 weeks and may protect against retinal detachments in patients with bilateral diffuse uveal melanocytic proliferation.
  • ||||||||||  fluocinolone acetonide / Generic mfg.
    Journal:  Polymeric Micelles Enhance Mucosal Contact Time and Deposition of Fluocinolone Acetonide. (Pubmed Central) -  Jun 11, 2022   
    In contrast, the FPM without SPA penetrated and passed through all layers. The FPM with extended mucoadhesion, improved drug-mucosal retention time, and increased FA permeation and deposition were successfully developed, and could be a promising innovation for increasing the efficiency of mouth rinses, as well as other topical pharmaceutical and dental applications.
  • ||||||||||  Triesence (triamcinolone acetonide injectable suspension) / Novartis, Kenalog-40 (triamcinolone acetonide injection suspension) / BMS
    Clinical, Review, Journal:  Efficacy and safety of intravitreal and periocular injection of corticosteroids in non-infectious uveitis: a systematic review. (Pubmed Central) -  Jun 8, 2022   
    The most frequently compared regimens were intravitreal triamcinolone acetonide injection and orbital floor triamcinolone acetonide injection (2 studies), intravitreal triamcinolone acetonide injection and posterior sub-Tenon triamcinolone acetonide injection (2 studies), and posterior sub-Tenon triamcinolone acetonide injection with the intravitreal dexamethasone implant (2 studies)...Moreover, the overall results of 0.59 mg dosage of the intravitreal fluocinolone acetonide implant were superior to those from the 2.1 mg dose. The evidence, however, is not robust and further studies with standardized outcomes are warranted.
  • ||||||||||  fluocinolone acetonide / Generic mfg.
    Trial completion date, Trial primary completion date:  PANTHER: Imaging of Uveitis Patients Receiving Injectable Fluocinolone Acetonide Implant (clinicaltrials.gov) -  Apr 28, 2022   
    P=N/A,  N=30, Recruiting, 
    The microemulsion demonstrating the greatest benefits was used in combination with ablative fractional lasering to treat scalp psoriasis. Trial completion date: Mar 2022 --> Mar 2023 | Trial primary completion date: Jan 2022 --> Jan 2023
  • ||||||||||  fluocinolone acetonide / Generic mfg.
    Biomarker, Journal:  Biomarkers to Predict the Success of Treatment with the Intravitreal 0.19 mg Fluocinolone Acetonide Implant in Uveitic Macular Edema. (Pubmed Central) -  Apr 24, 2022   
    A higher number of corticosteroids per year before FAc implantation was predictive for an increase in corticosteroids required after FAc (odds ratio = 2.65), while a decrease in CVI from baseline to 6 months was inversely correlated (odds ratio = 0.82). Our results suggest that the more corticosteroids prior to FAc and the greater the short-term CVI reducing effect, the less is the chance to get additional corticosteroids after FAc.
  • ||||||||||  Triesence (triamcinolone acetonide injectable suspension) / Novartis, Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
    Retrospective data, Review:  Comparative Efficacy and Safety of Advanced Intravitreal Therapeutic Agents for Noninfectious Uveitis: A Systematic Review and Network Meta-Analysis. (Pubmed Central) -  Apr 23, 2022   
    Background: To compare the efficacy and safety of advanced intravitreal therapeutic regimens, including a dexamethasone implant at 350 and 700 μg; a fluocinolone acetonide (FA) implant, 0.2 µg/day, 0.59 and 2.1 mg; intravitreal bevacizumab, 1.25 mg; intravitreal ranibizumab, 0.5 mg; intravitreal triamcinolone acetonide (IVTA), 2 and 4 mg; and standard of care (SOC, systemic therapy) for noninfectious uveitis...IVTA, 4 mg, might be the best choice with lowest risk of IOP rising. Systematic Review Registration: clinicaltrials.gov, identifier CRD42020172953.
  • ||||||||||  Triesence (triamcinolone acetonide injectable suspension) / Novartis
    Clinical, Review, Journal:  Corticosteroids in ophthalmology: drug delivery innovations, pharmacology, clinical applications, and future perspectives. (Pubmed Central) -  Apr 8, 2022   
    Prednisolone, prednisolone acetate, dexamethasone, triamcinolone acetonide, fluocinolone acetonide, and loteprednol etabonate are amongst the most widely used ophthalmic corticosteroids...Invasive drug administration via intracameral, subconjunctival, and intravitreal injection can enhance ocular bioavailability and minimize dose and dosing frequency of administration, yet may exacerbate ocular side effects of corticosteroids. This review provides a critical appraisal of the ophthalmic uses of corticosteroid, routes of administration, drug delivery fundamentals and novel ocular implantable steroid delivery systems, factors influencing side effects, and future perspectives for ocular corticosteroid therapy.
  • ||||||||||  dexamethasone / Generic mfg., fluocinolone acetonide / Generic mfg.
    Journal:  Steroid Treatment in Macular Edema: A Bibliometric Study and Visualization Analysis. (Pubmed Central) -  Mar 12, 2022   
    Macular edema, diabetic macular edema (DME), retinal vein occlusion (RVO), dexamethasone (DEX), fluocinolone acetonide (FA), and some other keywords were commonly studied in this field...While anti-VEGF therapy is the first-line treatment for DME and RVO-induced macular edema, steroids implant is a valid option for these DME patients not responding to anti-VEGF therapy and non-DME patients with macular edema. Combined therapy with anti-VEGF and steroid agents is vital for future research.
  • ||||||||||  fluocinolone acetonide / Generic mfg.
    Journal:  Switching to intravitreal fluocinolone acetonide implant for refractory diabetic macular edema: 12- and 24-month results. (Pubmed Central) -  Jan 21, 2022   
    Only five eyes required additional treatment for DME and only three eyes required treatment for raised IOP. Our results show that the visual and the anatomical improvements achieved by a single injection of a fluocinolone acetonide implant were maintained up to 24 months with minimal additional therapy even in eyes with a long and heavy history; however, IOP monitoring remains essential.
  • ||||||||||  fluocinolone acetonide / Generic mfg.
    Enrollment open, Trial completion date, Trial initiation date, Trial primary completion date, HEOR:  EMMA: Medico Economic Evaluation of Fluocinolone Acetonide Implant Versus Dexametheasone Implant in Resistant Diabetic Macular Oedema (clinicaltrials.gov) -  Nov 26, 2021   
    P4,  N=106, Recruiting, 
    A switch to Dexamethasone implant for patients receiving Aflibercept or Ranibizumab with minimal/no clinical benefit should be considered. Not yet recruiting --> Recruiting | Trial completion date: Jan 2027 --> Apr 2027 | Initiation date: Jul 2021 --> Oct 2021 | Trial primary completion date: Jan 2027 --> Apr 2027
  • ||||||||||  fluocinolone acetonide / Generic mfg.
    Clinical, Journal:  Vitreous expression of cytokines and growth factors in patients with diabetic retinopathy-An investigation of their expression based on clinical diabetic retinopathy grade. (Pubmed Central) -  Oct 9, 2021   
    P4
    Vitreous sampling was performed before treatment with fluocinolone acetonide and the extracted vitreous material was examined for the determination of GIF including interleukins 6 (IL-6) and 8 (IL-8), interferon gamma-inducible protein (IP-10), monocyte chemoattractant protein-1 (MCP-1), placental growth factor (PIGF), pigment epithelium-derived factor (PEDF), VEGF (vascular endothelial growth factor) and intercellular adhesion molecule (CD54)...Vitreous probes may be helpful in deciding which therapy to administer (i.e. anti-VEGF or corticosteroid or both) based on the expression of GIF. Registry EudraCT number: 2016-004488-38; DRKS-ID: DRKS00014915.
  • ||||||||||  clobetasol propionate topical / Generic mfg., fluocinolone acetonide / Generic mfg.
    Journal:  A Novel Approach to Assess the Potency of Topical Corticosteroids. (Pubmed Central) -  Sep 29, 2021   
    The potencies of clobetasol propionate, halcinonide, mometasone furoate, and fluocinolone acetonide were compared using the resulting E data following the fitting of the relevant response data to the E model where mometasone furoate > fluocinolone acetonide = clobetasol propionate > halcinonide. This ranking lists the respective inherent potencies of the APIs, which will facilitate the choice of a suitable candidate for incorporation into an appropriate topical corticosteroid product for a specific clinical indication.